Last reviewed · How we verify
BPG
BPG is a recombinant human blood product or biopharmaceutical candidate in development by Assistance Publique - Hôpitaux de Paris.
At a glance
| Generic name | BPG |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without publicly available detailed information on BPG's specific mechanism, it appears to be an investigational therapeutic in Phase 3 development. The exact molecular target and mechanism of action require access to clinical trial protocols or regulatory submissions from the sponsoring institution.
Approved indications
Common side effects
Key clinical trials
- Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting (NA)
- GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial (PHASE2)
- Congenital Syphilis Treatment Trial (CONSISTENT) in Neonates (PHASE4)
- Treatment Responses of Early Syphilis to Ceftriaxone Plus Doxycycline (PHASE4)
- A Non-Inferiority Trial of Stopping Penicillin in Early Rheumatic Heart Disease: GOAL-Stop (PHASE3)
- Clinical Trial of Doxycycline VS BPG for Early Syphilis (SY-DOXY) (PHASE3)
- Comparisons of Treatment Responses of Early Syphilis to Benzathine Penicillin G With or Without Doxycycline (NA)
- Evaluation of Antimicrobial Prophylaxis to Prevent Syphilis in Pregnancy in Patients at Risk in Rio de Janeiro, Brazil (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |